Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan 11;4(116):116ra4.
doi: 10.1126/scitranslmed.3002693.

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

Affiliations

Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy

Ovidiu C Andronesi et al. Sci Transl Med. .

Abstract

Mutations in the gene isocitrate dehydrogenase 1 (IDH1) are present in up to 86% of grade II and III gliomas and secondary glioblastoma. Arginine 132 (R132) mutations in the enzyme IDH1 result in excess production of the metabolite 2-hydroxyglutarate (2HG), which could be used as a biomarker for this subset of gliomas. Here, we use optimized in vivo spectral-editing and two-dimensional (2D) correlation magnetic resonance spectroscopy (MRS) methods to unambiguously detect 2HG noninvasively in glioma patients with IDH1 mutations. By comparison, fitting of conventional 1D MR spectra can provide false-positive readouts owing to spectral overlap of 2HG and chemically similar brain metabolites, such as glutamate and glutamine. 2HG was also detected using 2D high-resolution magic angle spinning MRS performed ex vivo on a separate set of glioma biopsy samples. 2HG detection by in vivo or ex vivo MRS enabled detailed molecular characterization of a clinically important subset of human gliomas. This has implications for diagnosis as well as monitoring of treatments targeting mutated IDH1.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
2D LASER-COSY and 1D MEGA-LASER spectra from brain phantoms at 3 T, with 3×3×3 cm3 voxels used in all measurements. (A) Overlay of 2D LASER-COSY spectra from a phantom containing a mixture of normal brain metabolites (red contours) and a phantom where 2HG was added to the mixture of normal brain metabolites (blue contours). The Hα-Hβ crosspeak of 2HG is at 4.02/1.91 (δ21) ppm. (B) Overlay of 1D MEGA-LASER from the same phantoms. The position of Hα peak of 2HG at 4.02 ppm lines with the crosspeak in the 2D spectrum above (dashed line). (C) Intensity of 2HG signal in 2D LASER-COSY and 1D MEGA-LASER at different 2HG concentrations (error bars represent one standard deviation of two independent measures, signal intensity is normalized (Inorm) to the maximum intensity). Other metabolites shown: choline (Cho), glutamate (Glu), lactate (Lac), myo-inositol (Myo), N-acetyl-aspartate (NAA).
Fig. 2
Fig. 2
HR-MAS spectra recorded at 14 T ex vivo on biopsy tissue from patients with and without IDH1 mutations. 1H-1H 2D TOBSY spectra are shown for all biopsies (the minimum contour levels were set five times the noise level). (A) For anaplastic astrocytoma biopsy tissue with IDH1R132 mutation (n=1), the spectra are shown in green-blue contours. The phantom is shown in red-yellow. Projections along δ1 and δ2 show the 2HG crosspeaks, outlined by a red rectangle. (B and C) Spectra for wt-IDH1 patients: primary glioblastoma (B; n=1) and non-tumor (C; n=1). The region where 2HG crosspeaks would be expected is outlined by a red rectangle. For all 2D TOBSY brain spectra, several other metabolites can be identified. Amino acids: alanine (Ala), aspartate (Asp), glutamate (Glu), glutamine (Gln), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), proline (Pro), serine (Ser), threonine (Thr). Membrane phospholipid-related compounds: choline (Cho), ethanolamine (Etn), glycerol (Glr), glycerophosphocholine (GPC), glycerophosphoethanolamine (GPE), phosphocholine (PC), phosphoethanolamine (PE). Sugars: l-fucose (lFuc), β-glucose (bGlc), myo-inositol (Myo). Miscellaneous: glutathione (GSH), lactate (Lac), lipids (Lip), N-acetyl-aspartate (NAA), and taurine (Tau).
Fig. 3
Fig. 3
2D LASER-COSY spectra in human subjects at 3 T. (A) An anaplastic astrocytoma patient with IDH1R132C. The 2D LASER-COSY shows at 4.02/1.91 ppm the Hα-Hβ crosspeak of 2HG. Projections along both spectral dimensions through 2HG crosspeak indicate the SNR and spectral quality. The single voxel (3×3×3 cm3, red rectangle) was placed on the FLAIR images to include most of the tumor abnormality. (B) A primary glioblastoma patient (wt-IDH1). The 2D LASER-COSY does not contain any 2HG crosspeak in the Hα-Hβ region outlined by the green rectangle. Projections through Glu+Gln crosspeak indicate spectral quality. The single voxel (3.5×3.5×3.5 cm3, red rectangle) was placed on the FLAIR images to include most of the tumor abnormality. (C) A healthy volunteer (wt-IDH1). 2HG is not found in the Hα-Hβ region of 2D LASER-COSY outlined by the green rectangle. Projections through Glu+Gln indicate spectral quality. The single voxel (3×3×3 cm3, red rectangle) was placed on the MEMPRAGE images in the white matter of the occipital lobe, in a region similar to tumor locations from patients in (A) and (B).
Fig. 4
Fig. 4
1D MEGA-LASER spectra in human subjects at 3 T. In all subjects two voxels (3×3×3 cm3 each) were placed in both brain hemispheres, symmetrically from the middle line. (A) A secondary glioblastoma patient with IDH1R132H mutation. (B and C) The spectra from subjects with wtIDH1—primary glioblastoma (B) and healthy volunteer (C). 2HG is present only in the tumor voxel of IDH1R132H patient. (MM denotes contamination of GABA signal with macromolecule signal).
Fig. 5
Fig. 5
Signal intensity ratios of 2HG to the sum of glutamate and glutamine (Glu+Gln). (A and B) Ratios are shown for all phantom and in vivo human spectra: 2D correlation MRS (LASER-COSY) (A), 1D spectral-edited MRS (MEGA-LASER) (B), and 1D conventional MRS (LASER) (A and B). Ratios are given as averages +/− one standard deviation. n = 2 for phantoms and IDH1R132 patients; n = 4 for wt-IDH1 subjects.

Similar articles

Cited by

References

    1. Parsons DW, Jones S, Zhang XS, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith DR, Strausberg RL, Marie SKN, Shinjo SMO, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Science. 2008 Sep;321:1807. - PMC - PubMed
    1. Chin L, Meyerson M, Aldape K, Bigner D, Mikkelsen T, VandenBerg S, Kahn A, Penny R, Ferguson ML, Gerhard DS, Getz G, Brennan C, Taylor BS, Winckler W, Park P, Ladanyi M, Hoadley KA, Verhaak RGW, Hayes DN, Spellman PT, Absher D, Weir BA, Ding L, Wheeler D, Lawrence MS, Cibulskis K, Mardis E, Zhang JH, Wilson RK, Donehower L, Wheeler DA, Purdom E, Wallis J, Laird PW, Herman JG, Schuebel KE, Weisenberger DJ, Baylin SB, Schultz N, Yao J, Wiedemeyer R, Weinstein J, Sander C, Gibbs RA, Gray J, Kucherlapati R, Lander ES, Myers RM, Perou CM, McLendon R, Friedman A, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Lehman N, Yung WKA, Bogler O, Berger M, Prados M, Muzny D, Morgan M, Scherer S, Sabo A, Nazareth L, Lewis L, Hall O, Zhu YM, Ren YR, Alvi O, Yao JQ, Hawes A, Jhangiani S, Fowler G, San Lucas A, Kovar C, Cree A, Dinh H, Santibanez J, Joshi V, Gonzalez-Garay ML, Miller CA, Milosavljevic A, Sougnez C, Fennell T, Mahan S, Wilkinson J, Ziaugra L, Onofrio R, Bloom T, Nicol R, Ardlie K, Baldwin J, Gabriel S, Fulton RS, McLellan MD, Larson DE, Shi XQ, Abbott R, Fulton L, Chen K, Koboldt DC, Wendl MC, Meyer R, Tang YZ, Lin L, Osborne JR, Dunford-Shore BH, Miner TL, Delehaunty K, Markovic C, Swift G, Courtney W, Pohl C, Abbott S, Hawkins A, Leong S, Haipek C, Schmidt H, Wiechert M, Vickery T, Scott S, Dooling DJ, Chinwalla A, Weinstock GM, O'Kelly M, Robinson J, Alexe G, Beroukhim R, Carter S, Chiang D, Gould J, Gupta S, Korn J, Mermel C, Mesirov J, Monti S, Nguyen H, Parkin M, Reich M, Stransky N, Garraway L, Golub T, Protopopov A, Perna I, Aronson S, Sathiamoorthy N, Ren G, Kim H, Kong SK, Xiao YH, Kohane IS, Seidman J, Cope L, Pan F, Van Den Berg D, Van Neste L, Yi JM, Li JZ, Southwick A, Brady S, Aggarwal A, Chung T, Sherlock G, Brooks JD, Jakkula LR, Lapuk AV, Marr H, Dorton S, Choi YG, Han J, Ray A, Wang V, Durinck S, Robinson M, Wang NJ, Vranizan K, Peng V, Van Name E, Fontenay GV, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Socci ND, Olshen A, Lash A, Reva B, Antipin Y, Stukalov A, Gross B, Cerami E, Wang WQ, Qin LX, Seshan VE, Villafania L, Cavatore M, Borsu L, Viale A, Gerald W, Topal MD, Qi Y, Balu S, Shi Y, Wu G, Bittner M, Shelton T, Lenkiewicz E, Morris S, Beasley D, Sanders S, Sfeir R, Chen J, Nassau D, Feng L, Hickey E, Schaefer C, Madhavan S, Buetow K, Barker A, Vockley J, Compton C, Vaught J, Fielding P, Collins F, Good P, Guyer M, Ozenberger B, Peterson J, Thomson E. Nature. 2008 Oct;455:1061. - PubMed
    1. Yan H, Parsons DW, Jin GL, McLendon R, Rasheed BA, Yuan WS, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. New England Journal of Medicine. 2009 Feb;360:765. - PMC - PubMed
    1. Kloosterhof NK, Bralten LBC, Dubbink HJ, French PJ, van den Bent MJ. Lancet Oncology. 2011 Jan;12:83. - PubMed
    1. Bleeker FE, Atai NA, Lamba S, Jonker A, Rijkeboer D, Bosch KS, Tigchelaar W, Troost D, Vandertop WP, Bardelli A, Van Noorden CJF. Acta Neuropathologica. 2011 Apr;119:487. - PMC - PubMed

MeSH terms